Kexing BiopharmEN
Home / Quality Control / Compliant produ...
Quality Control
Based on changes in the spectrum of human diseases and insight into the needs of doctors and patients, Sinovac adheres to people-oriented innovation.

Strategic Positioning & Planning: A characteristic leading enterprise in synthetic biology

Description: To become an industrial leader integrating research, production and sales in nutrition & health, beauty care, green agriculture and medical device market segments by grasping the strategic opportunity of the rapid development of synthetic biology, introducing and incubating internationally advanced synthetic biology platforms, quickly forming a product matrix with cost advantages and functional generation gaps, and occupying key links in the middle and upper reaches of the industrial chain.

Constructed in accordance with EU cGMP quality standards

Production Capacity

  • 60billionpieces

    Recombinant Protein Lyophilized Powder for Injection

  • 300billionbags

    Oral Microeconomics

  • 50billionpieces

    Genetically Engineered Injections

  • 20billionpieces

    Highly Complex injections

  • 1billionpieces

    Production capacity of traditional Chinese medicine preparations